Health issues
Pancreatic cancer
What is pancreatic cancer? Pancreatic cancer is the 4th cause of cancer deaths. In recent years the incidence of pancreatic cancer has continued to increase and today it accounts for 10-12 cases/100,000 persons. Pancreatic cancer develops from pre-cancerous lesions some of which are in the form of pancreatic cysts. Together with certain family factors, risk factors for this cancer are smoking, diabetes, alcohol consumption and obesity.   Care At our institutions we have developed a Fast Track care pathway for screening/diagnosing pancreatic cancer in all persons presenting a clinical (unexplained weight loss, jaundice, abdominal pain, decompensated diabetes) or radiological suspicion of cancer as well as for persons screened who are  at increased risk of pancreatic cancer (family history, chronic hereditary pancreatitis).  Following a pancreatic cancer diagnosis a complete medical check-up is carried out and the results discussed at a multidisciplinary meeting so as to decide on the line of treatment. If the pancreatic cancer is considered to be localised and resectable, pancreatic surgery can be envisaged, possibly  following  induction treatment (chemotherapy +/- radiotherapy). If it is non-resectable or metastatic, chemotherapy is proposed, possibly in the framework of study protocols. In Belgium, pancreatic surgery has been centralised since July 2019 at 15 experienced hospitals (including 6 French-speaking hospitals) with a high volume of pancreatic interventions so as to improve the care quality. The Erasmus Hospital is the leading French-speaking hospital in terms of the annual number of pancreatic surgery operations.     Research The HUB is active in developing new treatment approaches and initiated a multicentric study ((STEREOPAC) to assess the impact of stereotaxic radiotherapy (radiotherapy targeted at the tumour) following neoadjuvant chemotherapy in the case of localised pancreatic cancer .The Digestive Oncology Department is linked to the Laboratory of Experimental Gastroenterology (LGE) of the ULB’s Faculty of Medicine and to the Jules Bordet Institute’s GI Lab where a number of research projects are carried out, in particular on the immune-molecular impact of pancreatic cancer treatment.   A number of our doctors are members of various national and international groups of experts, namely :  the Belgian Group of Digestive Oncology, the Belgian Pancreatic Group, the Belgian Pancreatic Cancer Group, the European Society of Digestive Oncology and the European Society of Gastrointestinal Endoscopy. Our specialists Image Multidisciplinary bilio-pancreatic pathology group Associated services Publications Preoperative treatment with mFFX or GemNab and iHDSBRT (STEREOPAC trial) Authors : Bouchart et al Journal : BMC Cancer NAC associated with iHD-SBRT does not increase complications after PD Authors : Navez J et al Journal : J Surg Oncol Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features Authors : Puleo et al Journal : Gastroenterology Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST Authors : Bali et al Journal : Eur J Radiol
Pancreatic cancer
Health issues
Multiple system atrophy
What is systemic amyotrophy? under construction A service recognised as an expert centre ERN-RND ERN-RND – Expert Centres
Multiple system atrophy
Health issues
Carie dentaire
What is tooth decay? Tooth Decay is a common problem that occurs when the bacteria in the mouth cause the sugars to turn into acids.  This process leads to progressive demineralisation and the formation of dental cavities. If ignored, a cavity can worsen, causing pain, infection and sometimes the loss of the tooth. A rapid identification of the symptoms, such as an unusual sensitivity or discolouring, is essential for effective treatment.   Care Our clinic proposes a comprehensive care that combines prevention, early diagnosis and a variety of treatment, ranging from a simple filling to more complex procedures such as root canal treatment. Our collaborative approach that has recourse to specialists from various disciplines (speech therapist, ENT, stomatologist, hygienist, etc.) aims to provide individualised care and prevent further issues by educating patients in oral hygiene.  Advice to parents Preventing tooth decay in children starts with adopting healthy habits: brushing twice daily, limiting consumption of sweets and regular visits to the dentist.  Instilling good hygiene practices at a very young age is the foundation of long-term dental health.  Image Research Our commitment to research and innovation enables our patients to benefit from the latest developments in dental restoration materials and less invasive techniques for an improved management of tooth decay.  Our specialists Associated service
Carie dentaire
Health issues
Molar Incisive Hypomineralisation (MIH)
What is MIH? Molar Incisive Hypomineralisation is an anomaly of the enamel that gives rise to cream, yellow or brown stains on the teeth.  These stains are the result of insufficient mineralisation of the enamel during its development, making the teeth more vulnerable to decay and hypersensitivity. MIH affects approximately 15%  of children worldwide with variations depending on the geographical region. The exact causes of MIH remain to some extent unknown. Research nevertheless suggests that a role is played by a complex set of potential factors, including genetic and environmental elements and health issues during the first years of life.  Severe childhood illnesses between the ages of 0 and 4, the use of medicines and of anti-inflammatory drugs in particular, as well as certain prenatal and postnatal conditions, are all seen as factors contributing to the development of MIH. The signs of MIH include discoloured and stained molars and incisives. The affected teeth can become more sensitive, especially in response to cold, heat or sugar. In severe cases the enamel can erode, leading to cavities and pain that can potentially affect chewing and speech.   Treatment MIH is diagnosed during a thorough dental examination. A dentist is able to identify characteristic lesions of the tooth enamel and evaluate the extent of the problem. Treatment depends on the severity of the symptoms and can range from the application of fluoride varnish or dental cement to strengthen the enamel to more invasive treatment, especially if the tooth structure is seriously compromised.  Advice for parents Prevention and Early Detection: Make regular visits to the dentist as soon as the first permanent teeth appear for early detection. Oral hygiene: Encourage a strict brushing routine using fluoride toothpaste and also dental floss.Diet : Limit sugars and acids that can aggravate already vulnerable teeth. Professional treatment : Follow the dentist’s recommendations for protective or restorative treatment. MIH is a challenge for dentists as well as for the families who are affected by it. Nevertheless, with a clear and thorough understanding, early detection and proactive management it is possible to minimise its impact on the oral health of children. Parents have a key role to play in monitoring and caring for the dental health of their children and are encouraged to act in close cooperation with their dentist to ensure the best possible follow up. 
Molar Incisive Hypomineralisation (MIH)
Services
Vascular surgery
Our role The role of the vascular surgeon is to treat pathologies of the veins and arteries, with the exception of the heart, the proximal segment of the aorta and the brain. We devote much of our time in consultations to screening and considering cardiovascular risk factors. Our very close collaboration with Interventional Radiology and Medical Imaging provides us with rapid access to the diagnostic examinations that are essential in deciding on the best course of action for our patients, whether medical, surgical, endovascular or mixed.    Image Our specialities The Erasmus Hospital Vascular Surgery Department treats the following pathologies:     Arterial disease : Carotid surgery – Endovascular or surgical treatment of the abdominal aorta  – Arteriopathy of the lower limbs, etc. Venous diseases (phlebology), in particular symptoms of chronic venous insufficiency of the lower limbs: varicose veins, varicose ulcers, etc. Vascular acrosyndrome. Examples: Raynaud’s syndrome, chilblains, etc. Pathologies relating to coagulation disorders. Examples : thrombophilia, anticoagulation, venous thromboses (clot, pulmonary embolism). Vascular surgeons cooperate closely with their colleagues from the Diabetic Foot Clinic, the Stroke Center (Neurology) and Nephrology, principally in relation to vascular access for dialysis and kidney transplants. 
Chirurgie vasculaire
Health issues
Malnutrition
What is malnutrition? Malnutrition is a condition in which the body does not function properly because it lacks essential nutrients. These nutrients are carbohydrates, fats and proteins, also known as macronutrients. Image There are several reasons why someone might be deficient in these nutrients:They do not eat enough.Their body cannot digest or absorb the food they have eaten.They have a serious illness that changes their nutritional needs. In this case, we refer to disease-associated malnutrition.In addition to macronutrients, our body needs micronutrients such as vitamins, trace elements and minerals. The reasons for a micronutrient deficiency may differ from those for a macronutrient deficiency. Care management Managing malnutrition requires several steps:Early screening of patients at risk: It is important to identify patients at risk of malnutrition as soon as possible, during the first contact with the patient, in consultation or on admission to hospital.Diagnosis of malnutrition: This is made when a combination of a cause and a visible consequence is present (unintentional weight loss, a body mass index (BMI) below normal, or a decrease in muscle mass or strength).Setting nutritional goals: Healthcare professionals set energy and protein intake goals to enrich the patient’s diet.Checking food intake: We check whether the patient is meeting these goals. If not, oral nutritional supplements may be offered to be taken between meals.Enteral nutrition: If nutritional supplements are not sufficient, enteral nutrition may be considered. This means that the patient receives food through a tube that reaches the stomach.Parenteral nutrition: As a last resort, if enteral nutrition is insufficient, parenteral nutrition may be considered. This means that the patient receives nutrition directly into the veins.Managing malnutrition requires close collaboration between different healthcare professionals, such as doctors, dietitians, nurses, speech therapists and pharmacists. Concrete cases There are several situations in which people can become malnourished and need special assistance with eating. For example:People with upper gastrointestinal cancer may have difficulty eating enough. They may need a tube inserted into their stomach or small intestine to help them eat.People with an eating disorder such as anorexia may also become malnourished. They may temporarily require enteral nutrition, meaning special food adapted to what their body can use.After bariatric surgery, patients may absorb insufficient amounts of certain nutrients. They need nutritional supplements to help prevent this.After a cerebrovascular accident, patients may have difficulty swallowing. They may need food with a modified texture or, sometimes, enteral tube feeding if their level of consciousness is reduced. Focus Home enteral or parenteral nutrition is managed by an experienced multidisciplinary team (doctors, dietitians and nurses). They assist with the placement of feeding tubes, educate patients and their relatives, and organise consultations for close follow-up. Several hundred patients at Erasme benefit from this type of follow-up. We have all the necessary facilities to identify, manage and monitor patients through a multidisciplinary team with extensive expertise and genuine know-how.  We have developed particular expertise in monitoring the nutritional problems of patients with pancreatic disease and oesophageal disease, for whom Erasme Hospital is an expert centre, thanks to our dedicated team and cutting-edge technologies.  The approved centre for parenteral nutrition has a multidisciplinary team that works closely together to ensure optimal care for patients requiring long-term parenteral nutrition following benign or malignant intestinal diseases. Erasme Hospital is an excellent choice for patients seeking high-quality care and long-term follow-up for diseases requiring specialised nutritional management.  Our specialists Associated services Publications Practical ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznarić Ž, Lobo DN, Löser C, Madl C, Meier R, Phillips M, Rasmussen HH, Van Hooft JE, Bischoff SC.Clin Nutr. February 2024;43(2):395–412.  Dietary strategies in patients with non-alcoholic fatty liver disease: from evidence to daily clinical practice—a systematic review. Hadefi A, Arvanitakis M, Trépo E, Zelber-Sagi S.United European Gastroenterol J. 2023 Sep;11(7):663-689. Percutaneous endoscopic jejunostomy: when, how, and when to avoid it. Gkolfakis P, Arvanitakis M.Curr Opin Gastroenterol. 2022 May 1;38(3):285-291.  Lien vers https://www.amub-ulb.be/revue-medicale-bruxelles/article/risque-de-denutrition-… Risk of malnutrition and confirmed malnutrition: updated diagnostic criteria. Preiser JC, Farine S.Rev Med Brux 2022;43(1):7-11. 
Malnutrition
Health issues
Monogenic infertility
Nos spécialistes Service associé
Monogenic infertility
Health issues
Idiopathic hypersomnia
Nos spécialistes Service associé
Idiopathic hypersomnia
Health issues
Narcolepsy
What is narcolepsy? Narcolepsy is a rare chronic neurological disorder that affects the brain’s ability to regulate the sleep–wake cycle. Type 1 narcolepsy is caused by reduced production of a substance called hypocretin (or orexin), produced by specialised neurons in the hypothalamus and responsible for alertness (the state of wakefulness). This loss is most often autoimmune in origin. The pathophysiology of type 2 narcolepsy is less well understood: hypocretin levels in the cerebrospinal fluid are normal, and the mechanisms involved have not yet been clearly established.Narcolepsy frequently begins during childhood or adolescence, with an initial peak between the ages of 10 and 15, followed by a second peak around the ages of 30 to 35. Diagnosis is often delayed by several years because of atypical presentations in children. What are the symptoms? Narcolepsy manifests through four main symptoms (the “tetrad”):•  Excessive daytime sleepiness (EDS): an irresistible urge to sleep during the day, even after a full night’s sleep, generally manifesting as falling asleep and sleep attacks that occur suddenly during the day, during less stimulating activities (while travelling by car/on public transport, in class during lessons, on the sofa while watching TV, etc.). In children, this may also manifest as irritability, hyperactivity or difficulty concentrating.•  Cataplexy: sudden and brief loss of muscle tone, generally triggered by a positive emotion (laughter, surprise, etc.). It may be partial (drooping of the head, weakness in the arms, buckling of the legs) or complete. It is characteristic of type 1 narcolepsy.•  Hypnagogic/hypnopompic hallucinations: visual or auditory hallucinations occurring when falling asleep or waking up; they can be frightening.•  Sleep paralysis: inability to move for a few seconds to a few minutes during the transition from sleep to wakefulness. This paralysis can cause anxiety, but it always resolves after a few seconds/minutes.Associated symptoms are common: weight gain, behavioural disorders (aggressiveness, anxiety, automatic behaviours), depression and precocious puberty. How is the diagnostic process carried out at ERASME? If narcolepsy is suspected, patients will be offered a consultation at the Sleep Clinic to undergo a complete medical history, a neurological examination and blood tests (routine tests, thyroid function tests, serology and HLA typing). Measures to ensure good sleep hygiene and a sleep diary will be implemented for at least 4 weeks before the remainder of the complementary assessment is carried out. Medications that may influence the tests will also be discontinued beforehand. The diagnostic assessment takes place over 3 days of hospitalisation in our unit. This will be preceded by actigraphy (a “kind of smart watch”), to be worn at home for 2 weeks before the sleep testThe sleep test takes place in several stages:Standard polysomnography (PSG) over 2 nights. A daytime multiple sleep latency test (MSLT): 4 to 5 scheduled naps at 2-hour intervals. Continuous recording over 24 hours to document a total sleep time of ≥ 660 minutes (11 hours). Other examinations will also be arranged on an outpatient basis (optional):A neuropsychological assessmentA brain MRIAn Endocrinology consultation may also be offered depending on the hormonal assessment In certain cases, a lumbar puncture may be proposed at a later stage to measure the hypocretin level in the cerebrospinal fluid and confirm or rule out a diagnosis of type 1 narcolepsy.What treatments are available?There is currently no curative treatment. Treatments are symptomatic and aim to improve quality of life.Non-medication measures:Regular sleep scheduleScheduled daytime naps (1–2 naps of 20 minutes)Regular physical activityEducational or occupational adjustments (additional time during examinations, adapted schedules, justified absences)Medication treatments (prescription-only and requiring specialist follow-up):•  Modafinil (Provigil): first-line treatment for excessive daytime sleepiness•  Pitolisant (Wakix): an alternative, effective against sleepiness and cataplexy• Sodium oxybate (Xyrem): for moderate to severe forms with cataplexy and sleep fragmentation.•  Other options: methylphenidate or venlafaxine, depending on the situationTreatments are reimbursed in Belgium subject to INAMI conditions (confirmed diagnosis and clinical criteria) Who are the professionals involved in your care? Neurologists / sleep specialistCare pathway coordinator: Prof. Mélanie StraussProfessionals responsible for diagnosis, treatment and specialised follow-up:               Prof. Mélanie Strauss, Dr Faustine LeboutGeneral practitionerFirst-line follow-up and coordination with the specialist. Other professionals may be involved in your care pathway, including:• Neuropsychologists and psychologists: Comprehensive neuropsychological assessment of cognitive functions. Assessment of comorbidities such as attention deficit hyperactivity disorder, both at diagnosis and during treatment. Psychoeducation and support regarding the impact of the condition on schooling/work, self-esteem and social life.• Endocrinology : hormonal disorders, diabetes• Gastroenterology and hepatology  : overweight clinic• ENT and Pneumology: Management of sleep apneaSchool/Work: Medical certificate to put reasonable accommodations in place. Coordination with the PMS Centre if necessary. Useful links European Narcolepsy Network (EU-NN) Orphanet (medical information, ORPHA code) Association of narcoleptic patients in Belgium Our specialists Associated department
Narcolepsy
Health issues
Kleine–Levin syndrome
What is Kleine–Levin syndrome? Kleine-Levin syndrome (KLS) is a rare intermittent neuropsychiatric disorder (approximately 3 cases per million) that predominantly affects adolescents and young adults. It is characterised by symptomatic periods (“episodes” or “attacks”) lasting from one to several weeks, combining severe hypersomnia with cognitive, behavioural and psychiatric disorders.The episodes are separated by intercritical periods lasting from several weeks to several months, with a return to normal functioning.The course is variable, averaging around twenty episodes, and is often favourable: the disorder frequently disappears after the age of thirty.This favourable prognosis should not obscure the fact that some patients experience very distressing episodes (marked derealisation, sometimes severe behavioural disorders involving hyperphagia, hypersexuality, aggression, delusions or suicidal thoughts), prolonged episodes (lasting more than a month) or very frequent episodes, which affect their school, professional and family life.Furthermore, around one-third of young people develop, as a result of experiencing repeated episodes, persistent mild cognitive impairment between attacks, sleep disorders, anxiety or mood disorders. This is why it is important to make the diagnosis and, often, to treat these disorders. What are the symptoms? The classic presentation is that of an adolescent with no previous medical history who suddenly begins sleeping continuously (18 hours or more per day), stays in their room, lying down, confused, slowed down and apathetic (for example, no longer using their mobile phone), and experiences derealisation (the feeling of being in a dream). The episode lasts one or two weeks, after which the young person returns to completely normal. During the episode, varying degrees of severe anxiety, sadness, disinhibited behaviour (megaphagia, hypersexuality, rudeness) or delusional ideas may also occur. Since the first episode is often triggered by an infection or alcohol consumption, the doctor often suspects a viral illness or substance use, performs a brain MRI (normal), sometimes a lumbar puncture (normal), or recommends consulting a psychiatrist. A recurrence of the same symptoms several weeks or months later should suggest Kleine–Levin syndrome. How is the diagnosis carried out at Erasme? The diagnosis is mainly clinical: description, observation or video recording of the episodes by the family, and exclusion of other more common diagnoses. However, frequent abnormalities may be observed on the EEG during an episode and on functional brain imaging (PET scan), even during asymptomatic periods: hypometabolism of the posterior association cortex or hippocampus in 70% of cases. Predisposing factors include male sex and neonatal disorders. The cause is unknown, but some indirect evidence suggests that this is a recurrent inflammatory encephalopathy. What treatments are available? General management- Explanation of the disease: current knowledge and patient association.- Reduction of factors that trigger episodes: no alcohol or cannabis, sufficient and regular sleep, preventive measures, seasonal influenza and COVID-19 vaccination, and treatment of infections.- In the event of an episode: keep the patient at home, resting quietly in bed and often in the dark, under the supervision of the family, ensuring that they drink enough and eat a little. Urination is maintained. Never drive a vehicle during an episode (risk of an accident). Bring the patient home if an episode begins abroad.- Hospitalisation: only if there is a risk to the patient or others (severe delirium, suicidal thoughts, aggression).Drug treatmentThe treatment is selected and regularly reassessed by the neurologists responsible for the patient’s care. No treatment is also an option. However, on a case-by-case basis, depending on the degree of disability, particularly if the episodes are frequent (> 3/year), prolonged (> 1 month), or involve significant psychiatric symptoms, the following is recommended:Lithium at a therapeutic dose: beneficial in more than 83% of cases. It requires drinking plenty of fluids (water!), regular monitoring of lithium levels, TSH and creatinine levels, and an annual reassessment of its effectiveness. Please note that this disease is unrelated to bipolar disorder. Lithium is then gradually discontinued after 3 years without an episode.Treatment during an episode: intravenous methylprednisolone may be started at a dose of 1 gram/day for 3 consecutive days, with gastric protection. Who are the professionals involved in your care? NeurologistsCare pathway coordinator: Prof. Mélanie Strauss. Dr Faustine Lebout Experts in diagnosis, treatment and specialised follow-up.General practitionerFirst-line follow-up and coordination with the specialist.NeuropsychologistComprehensive neuropsychological assessment and coordinated support by Mr Hichem SlamaPsychoeducation. Support in coping with the impact of the disease, self-esteem and social life.Psychologist / child and adolescent psychiatristIn the event of anxiety or depressive symptoms, or difficulties adapting related to the disease. Useful links Orphanet (medical information, ORPHA code) Our specialists
Kleine–Levin syndrome
Health issues
Rare ataxia
Nos spécialistes Service associé
Rare ataxia
Health issues
Huntington’s disease
Our specialists Associated services
Huntington’s disease